DYAI

Dyadic and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine Development

Dyadic expands infectious disease collaboration with Scripps using C1 platform for rapid biologics

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>&lt;link type=&quot;text/css&quot; rel=&quot;stylesheet&quot; href=&quot;https://www.globenewswire.com/styles/gnw_nitf.css&quot;&gt;&lt;/li...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Dyadic Applied BioSolutions and Scripps Research will evaluate monoclonal antibodies and vaccine candidates against hantaviruses using the C1 platform, aiming for faster, scalable biologics. The collaboration builds on prior Andes virus work and leverages funding from Gates Foundation, CEPI, FBS, and EU initiatives. Success could broaden Dyadic&#039;s infectious-disease manufacturing partnerships and potential non-dilutive funding.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Dyadic and Scripps Research to evaluate hantavirus antibodies and vaccines.</li><li>C1 platform aims for rapid development, high productivity, scalable manufacturing.</li><li>Funding from Gates Foundation, CEPI, FBS, EU ZAPI supports work.</li><li>Cooperation adds pandemic preparedness angle; could broaden revenue channels.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Dyadic International, Inc. (DYAI)</strong>: Announces collaboration with Scripps; C1 platform validation and potential funding-driven upside.</li><li><strong>Scripps Research (N/A)</strong>: Academic partner evaluating hantavirus antibodies and vaccines; enhances platform credibility.</li><li><strong>Gates Foundation (N/A)</strong>: Funding support for recombinant protein vaccines and antibody workflows using C1; potential non-dilutive support.</li><li><strong>Coalition for Epidemic Preparedness Innovations (CEPI) (N/A)</strong>: Grant support for vaccine/antibody development workflows using C1; collaborative funding signal.</li><li><strong>Fondazione Biotecnopolo di Siena (FBS) (N/A)</strong>: Collaborating with CEPI and Gates; co-funding acceleration programs for C1-driven projects.</li><li><strong>Zoonosis Anticipation and Preparedness Initiative (ZAPI) EU (N/A)</strong>: EU pandemic preparedness program previously included C1; ongoing relevance to deployment.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>Category: Corporate Developments. The story centers on a strategic collaboration and funding support, signaling validation of Dyadic&#039;s C1 platform and potential future revenue via partnerships and grants, rather than immediate product sales.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Collaboration with Scripps Research validates Dyadic&#039;s C1 platform in infectious disease.</li><li>Grants from Gates Foundation, CEPI, FBS, EU ZAPI signal non-dilutive funding.</li><li>No immediate revenue; milestone-based payments could lift sentiment.</li><li>R&amp;D expansion toward vaccine and antibody programs may broaden addressable markets.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Date: May 28, 2026.</li><li>C1 platform used for vaccine antigens and monoclonal antibodies against RSV, malaria, Andes virus, Ebola, and Marburg.</li><li>Funding/support from Gates Foundation, CEPI, FBS; ZAPI EU program cited.</li><li>GMP manufacturing and Phase 1 evaluation previously demonstrated with the C1 platform.</li><li>Andes virus work includes rANDV-44 antibody showing neutralization activity vs pseudovirus.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Near-term: neutral; potential upside if new grants/partnerships translate into funded manufacturing deals.</p>
  </section>
</section>


<article>
  <h2>Dyadic and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine Development</h2>

  <p>Dyadic Applied BioSolutions and researchers at Scripps Research have begun a collaboration to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses, including Andes virus. The effort leverages Dyadic’s C1 platform to support rapid development timelines, high-productivity microbial fermentation, and large-scale manufacturing for future infectious disease preparedness. The collaboration was announced from Jupiter, Florida on May 28, 2026. The company trades on the NASDAQ under the symbol <strong>DYAI</strong>.</p>

  <section>
    <h3>Collaboration Overview and Strategic Context</h3>
    <p>A series of recently reported hantavirus and Ebola cases worldwide have underscored the importance of pandemic preparedness and highlighted the need to improve the speed, scalability, flexibility, and cost-effectiveness of biologic manufacturing during rapidly evolving public health events. The collaboration builds upon Dyadic's prior Andes virus monoclonal antibody work and combines the complementary expertise of Dyadic and Scripps Research to further assess the potential of Dyadic's proprietary C1 platform for rapid development timelines, high-productivity microbial fermentation, large-scale manufacturing, and biologic production intended to support future infectious disease preparedness.</p>
  </section>

  <section>
    <h3>C1 Platform Capabilities Across Biologic Modalities</h3>
    <p>Dyadic's microbial fungal-based C1 platform has been applied to multiple biologic modalities, including recombinant vaccine antigens and monoclonal antibodies targeting RSV, malaria, the Andes virus, Ebola, and Marburg, which is similar to Ebola and comes from the same family of viruses—the Filovirus family, and has demonstrated in preclinical studies the ability to produce monoclonal antibodies with binding, neutralization, and efficacy characteristics comparable to those generated by traditional mammalian expression systems.</p>

    <p>In prior Andes virus-related work, Dyadic developed a C1 strain expressing the recombinant anti-Andes virus monoclonal antibody rANDV-44, where, Dyadic believes, the data generated demonstrated virus neutralization activity comparable to ExpiCHO-produced material in a pseudovirus neutralization assay.</p>
  </section>

  <section>
    <h3>Previous Manufacturing Achievements and Ongoing Collaborations</h3>
    <p>Dyadic has also previously demonstrated GMP-compliant manufacturing and Phase 1 clinical evaluation of biologics produced using its C1 platform as part of earlier infectious disease initiatives. The Company is currently involved in multiple funded biopharmaceutical collaborations, including programs supported by the Gates Foundation and the Coalition for Epidemic Preparedness Innovations ("CEPI") in collaboration with Fondazione Biotecnopolo di Siena ("FBS"), aimed at accelerating recombinant protein vaccines and monoclonal antibody development workflows using the C1 platform.</p>

    <p>Dyadic's C1 platform was previously included in the European Union-supported Zoonosis Anticipation and Preparedness Initiative ("ZAPI"), a five-year pandemic preparedness program involving leading global human and animal health organizations focused on accelerating biologic manufacturing technologies for emerging infectious diseases. Building upon the progress achieved from ZAPI, Dyadic's more recent and ongoing funded collaborations supported by the Gates Foundation, CEPI, FBS, and activities associated with the EU Vaccine Hub continue to advance rapid, scalable biologic manufacturing approaches using the C1 platform to help address many of the manufacturing bottlenecks revealed during COVID-19 and other emerging infectious disease outbreaks.</p>
  </section>

  <section>
    <h3>Data, Advantages, and Scientific Rationale</h3>
    <p>Together, these programs continue to generate data that support the potential advantages of the C1 platform, including compressed development timelines, scalable microbial fermentation, and streamlined manufacturing processes. Additional studies have shown that C1-produced monoclonal antibodies can achieve binding and neutralization properties comparable to antibodies produced in traditional mammalian systems.</p>
  </section>

  <section>
    <h3>Executive Commentary</h3>
    <blockquote>
      <p>"One of the key lessons from recent global outbreaks is that scientific innovation alone is not sufficient — manufacturing flexibility, scale and speed are also critical," said Jiang Zhu, Professor at Scripps Research. "Collaborations that bring together advanced antibody and antigen research with rapid biologic production technologies may help strengthen preparedness for future infectious disease threats."</p>
    </blockquote>

    <blockquote>
      <p>Dr. Zhu continued, "My laboratory at Scripps Research has developed proprietary structure-based protein designs optimized for conformational integrity, trimer closure, and antigen quality. In parallel, innovative expression technologies such as Dyadic's C1 platform may offer opportunities to further evaluate faster, more scalable and potentially lower-cost approaches for the development and manufacture of complex biologics targeting emerging infectious diseases."</p>
    </blockquote>

    <blockquote>
      <p>"COVID-19 demonstrated that manufacturing scalability and deployment speed remain critical challenges during global outbreaks," said Mark Emalfarb, Dyadic's Chief Executive Officer. "Our collaboration with Scripps builds upon prior hantavirus-related work and reflects our broader strategy of partnering with leading research institutions and global health organizations to evaluate how we anticipate the C1 platform will contribute to future pandemic preparedness initiatives."</p>
    </blockquote>

    <blockquote>
      <p>Mr. Emalfarb continued, "Importantly, these activities continue to be pursued through grants, sponsored research, and strategic collaborations, allowing Dyadic to further validate the C1 platform in a capital-efficient manner while maintaining our primary commercial focus on non-pharmaceutical protein products and industrial-scale biomanufacturing opportunities."</p>
    </blockquote>
  </section>

  <section>
    <h3>Future Outlook and Collaboration Plan</h3>
    <p>Dyadic and Scripps plan to jointly explore external partnership and non-dilutive funding opportunities to support additional development activities related to monoclonal antibodies, and vaccine candidates, and broader infectious disease preparedness applications.</p>

    <p>Dyadic recently highlighted growing commercial activity with recombinant proteins and enzymes in non-pharmaceutical applications, including animal-free proteins for life sciences, cell culture media, nutrition, wellness, and industrial markets.</p>
  </section>

  <section>
    <h3>About Dyadic Applied BioSolutions</h3>
    <p><strong>About Dyadic Applied BioSolutions</strong> is a global biotechnology company that aims to develop and commercialize scalable, non-animal protein production platforms to meet growing global demand across the life sciences, food and nutrition, and bio-industrial markets. These high-value proteins are designed to enable customers to develop more efficient, scalable, and sustainable products. Dyadic's proprietary Dapibus™ and C1 expression systems support rapid, cost-effective, and flexible manufacturing.</p>

    <p>For more information, please visit <a href="http://www.dyadic.com" rel="nofollow" target="_blank">http://www.dyadic.com</a>.</p>
  </section>

  <section>
    <h3>Forward-Looking Statements and Safe Harbor</h3>
    <p><strong>Safe Harbor Regarding Forward-Looking Statements</strong></p>
    <p>This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act, including those regarding Dyadic International's expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance, such as the success of our clinical trial and interest in our protein production platforms, our research projects and third-party collaborations, as well as the availability of necessary funding. Forward-looking...</p>
  </section>

  <section>
    <h3>Key Facts and Quick Reference</h3>
    <ul>
      <li>Partnership between Dyadic Applied BioSolutions and Scripps Research to evaluate hantavirus monoclonal antibodies and vaccine candidates, including Andes virus (HPS).</li>
      <li>Focus on accelerating development timelines, high-productivity microbial fermentation, and large-scale manufacturing using the C1 platform.</li>
      <li>Prior Andes virus work includes the C1 strain expressing the anti-Andes virus monoclonal antibody rANDV-44, with data indicating virus neutralization activity comparable to ExpiCHO-produced material in a pseudovirus neutralization assay.</li>
      <li>Dyadic has GMP-compliant manufacturing and Phase 1 clinical evaluation of biologics produced with the C1 platform.</li>
      <li>Current funded collaborations include Gates Foundation and CEPI programs in collaboration with FBS, aimed at accelerating recombinant protein vaccines and monoclonal antibody development workflows using the C1 platform.</li>
      <li>Past EU ZAPI program and ongoing initiatives with Gates Foundation, CEPI, FBS, and EU Vaccine Hub support rapid, scalable biologic manufacturing to address bottlenecks from COVID-19 and other outbreaks.</li>
      <li>Dyadic's C1 platform demonstrates potential advantages such as compressed development timelines, scalable microbial fermentation, and streamlined manufacturing; C1-produced antibodies may exhibit binding and neutralization properties comparable to mammalian systems.</li>
      <li>Stock symbol: <strong>DYAI</strong> (NASDAQ).</li>
    </ul>
  </section>
</article>

Dyadic Applied BioSolutions and Scripps Research will evaluate monoclonal antibodies and vaccine candidates against hantaviruses using the C1 platform, aiming for faster, scalable biologics. The collaboration builds on prior Andes virus work and leverages funding from Gates Foundation, CEPI, FBS, and EU initiatives. Success could broaden Dyadic's infectious-disease manufacturing partnerships and potential non-dilutive funding.

Dyadic and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine Development

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News